A 77-year-old man who developed pancytopenia was administered granulocyte colony-stimulating factor (G-CSF) 
Introduction

Therapy-related leukemia caused by systemic chemotherapy is increasing (1). Acute meloid leukemia (AML) is one of the most frequent types (1), and there have been occasional cases of acute promyelocytic leukemia (APL): 30 cases as of 1995 have been reported including case reports and a literature review (2, 3). The precise incidence of therapy-related APL has not been described (1-3). These cases usually involve patients treated with systemic oral or intravenous administration of chemotherapeutic agents including alkylating agent and topoisomerase II inhibitor, and radiation. For patients with hepatocellular carcinoma, a case of therapy-related AML was reported who was treated with intra-atrial and intravenous injections of chemotherapeutic agents, and radiation (4)
.
T a b l e 2 . P l a s ma L e v e l s o f Cy t o k i n e s d u r i n g t h e Ad mi n i s t r a t i o n o f AT RA ( No r ma l Ra n g e i s Gi v e n i n P a r e n t h e s e s )
F i g u r e 1 . Cl i n i c a l Co u r s e .
F i g u r e 2 . Co mp u t e d t o mo g r a p h y ( CT ) o f t h e a b d o me n s h o wi n g a t r o p h y o f t h e l i v e r a n d a s c i t e s .
tic circulatory failure, although the causative pathogen was unknown.
Discussion
The present case highlighted several issues. Leukopenia or pancytopenia is frequently observed in patients with APL at diagnosis, as in the present patient (7). Also, leukemic cells are stimulated to increase by the preceeding administration of G-CSF. In the present patient, pancytoepnia including neutropenia was observed before and after the administration of G-CSF. The administration of G-CSF in patients with AML is usually contraindicated in the presence of leukemic blasts. The cause of pancytopenia should be carefully evaluated before the administration of G-CSF in patients with leukopenia. In the present patient, APL was therapy-related rather than de novo, since chromosome analysis demonstrated del(7) in addition to t(15;17); the former is usually observed in patients with therapy-related leukemia (1). The loss of an entire chromosome or deletion of various parts of chromosome 7 or 5 has been frequently observed in therapy-related AML and myelodysplastic syndrome (1).
The frequency of chromosome 7 abnormality in therapyrelated APL has been described only in one case report (3) ; however, cumulative data have not been reported in the literature reviews (2, 3) .
About 30 patients with therapy-related APL caused by the alkylating agent, topoisomerase II inhibitor, and radiation, were reviewed in the literature (3 
